PMS2 and endometrial cancer: In a study by Backes et al.23 examining the results of 140 patients with endometrial cancer, dMMR was observed in 21% of the patients, and the most frequently detected protein expression loss was MLH1 and PMS2, observed in 17.1% of the patients.